Loading
A phase 2/3 trial of Fianlimab, Cemiplimab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer is a phase 2/3 interventional study registered as NCT05800015 by Regeneron Pharmaceuticals, with 160 participants enrolled, started 2023-08-08 and due to reach its primary completion in 2030-01-16. Interventions recorded: fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Fianlimab, Regeneron, Cemiplimab, Pemetrexed.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.